Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label study of SU011248 in advanced/metastatic gastric cancer after one prior chemotherapy
2005-000524-16Phase 2Completed
- Sponsor
- Pfizer
- Start
- Nov 2005
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunitinib in gastric adenocarcinoma and gastroesophageal junction adenocarcinoma, sponsored by Pfizer. Primary endpoint: Objective response rate. Started Nov 2005; status: completed.
02
Drugs
sunitinib
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on 2005-000524-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-000524-16.